source
- Dr Randall explains rationale for CSF-1R inhibitor pimicotinib in tenosynovial giant cell tumor trialDr Randall, a professor at UC Davis Comprehensive Cancer Center, discussed the clinical reasoning behind testing the selective CSF-1R inhibitor pimicotinib (ABSK021) for tenosynovial giant cell tum…
- Experts discuss how real-world patient factors shape first-line renal cell carcinoma treatment choicesDr. Elizabeth Plimack and Dr. Yasser Ged appeared in a recent segment to talk about first-line treatment selection for renal cell carcinoma. They explained that beyond clinical trial results, real…